MRNA vs. DNA

In the year-to-date period, MRNA achieves a -34.54% return, which is significantly lower than DNA's -20.16% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MRNA Sharpe Ratio is -1.08, which is lower than the DNA Sharpe Ratio of -0.68. The chart below compares the historical Sharpe Ratios of MRNA and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither MRNA nor DNA has paid dividends to shareholders.

The maximum MRNA drawdown since its inception was -94.94%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for MRNA and DNA. For additional features, visit the drawdowns tool.

The current volatility for Moderna, Inc. (MRNA) is 21.32%, while Ginkgo Bioworks Holdings, Inc. (DNA) has a volatility of 32.07%. This indicates that MRNA experiences smaller price fluctuations and is considered to be less risky than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Moderna, Inc. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.